Abstract PD1-06: A phase 1b dose-escalation and expansion study of the BCL-2 inhibitor venetoclax combined with tamoxifen in ER and BCL-2–positive metastatic breast cancer (MBC)
Lindeman, GJ, Lok, SW, Whittle, JR, Siow, ZR, Bergin, AR, Dawson, S-J, Desai, J, Gray, DH, Liew, D, Mann, GB, Murugasu, A, Roberts, AW, Rosenthal, MA, Shackleton, K, Sherman, P, Silva, MJ, Teh, C, Travers, A, Vaillant, F, Visvader, JE
Published in Cancer research (Chicago, Ill.) (15.02.2019)
Published in Cancer research (Chicago, Ill.) (15.02.2019)
Get full text
Journal Article
Abstract P3-11-05: RANK ligand is a target for breast cancer prevention in BRCA1 mutation carriers
Lindeman, GJ, Nolan, E, Pal, B, Vaillant, F, Giner, G, Whitehead, L, Mann, GB, Lok, SW, Shackleton, K, Smyth, GK, Visvader, JE
Published in Cancer research (Chicago, Ill.) (15.02.2016)
Published in Cancer research (Chicago, Ill.) (15.02.2016)
Get full text
Journal Article
Abstract S2-04: RANK ligand as a target for breast cancer prevention in BRCA1 mutation carriers
Lindeman, GJ, Nolan, E, Vaillant, F, Branstetter, D, Pal, B, Giner, G, Whitehead, L, Lok, SW, Mann, GB, kConFab, Consortium, Rohrbach, K, Huang, L-Y, Soriano, R, Smyth, GK, Dougall, WC, Visvader, JE
Published in Cancer research (Chicago, Ill.) (15.02.2017)
Published in Cancer research (Chicago, Ill.) (15.02.2017)
Get full text
Journal Article